HN2001000110A - 5-cloro -3-(metansulfonilfelino)-6-metil-[2.3] bipiridinilo en forma cristalina pura y proceso para la sintesis - Google Patents

5-cloro -3-(metansulfonilfelino)-6-metil-[2.3] bipiridinilo en forma cristalina pura y proceso para la sintesis

Info

Publication number
HN2001000110A
HN2001000110A HN2001000110A HN2001000110A HN2001000110A HN 2001000110 A HN2001000110 A HN 2001000110A HN 2001000110 A HN2001000110 A HN 2001000110A HN 2001000110 A HN2001000110 A HN 2001000110A HN 2001000110 A HN2001000110 A HN 2001000110A
Authority
HN
Honduras
Prior art keywords
polymorphic form
metansulfonilfelino
bipiridinyl
chlorine
synthesis
Prior art date
Application number
HN2001000110A
Other languages
English (en)
Inventor
Louis S Crocker
Ian W Davies
Richard G Osifchin
Kotliar Andrew
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22772880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2001000110(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of HN2001000110A publication Critical patent/HN2001000110A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Este invento comprende la Forma V polimorfa de fórmula estructural Que es útil en el tratamiento de enfermedades mediadas por la ciclooxigenasa-2. EL invento comprende ciertas composiciones farmacéuticas para el Tratamiento de enfermedades mediadas por la ciclooxigenasa-2, que comprenden la Forma V polimorfa del Compuesto A. El invento también comprende un proceso para Sintetizar La Forma V polimorfa del Compuesto A, que comprende: combinar las Formas polimorfas I, 11, 1111 o IV del Compuesto A con acetato isopropílico, calentando A una temperatura elevada inferior a 75 DEG C y enfriando a una temperatura baja, para Producir la Forma V polimorfa.
HN2001000110A 2000-05-26 2001-05-23 5-cloro -3-(metansulfonilfelino)-6-metil-[2.3] bipiridinilo en forma cristalina pura y proceso para la sintesis HN2001000110A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20801700P 2000-05-26 2000-05-26

Publications (1)

Publication Number Publication Date
HN2001000110A true HN2001000110A (es) 2002-03-06

Family

ID=22772880

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2001000110A HN2001000110A (es) 2000-05-26 2001-05-23 5-cloro -3-(metansulfonilfelino)-6-metil-[2.3] bipiridinilo en forma cristalina pura y proceso para la sintesis

Country Status (49)

Country Link
EP (1) EP1296951B1 (es)
JP (2) JP3665053B2 (es)
KR (1) KR100757699B1 (es)
CN (1) CN1227233C (es)
AR (1) AR028577A1 (es)
AT (1) ATE483687T1 (es)
AU (2) AU6480401A (es)
BG (1) BG65855B1 (es)
BR (1) BRPI0111140B8 (es)
CA (1) CA2410234C (es)
CR (1) CR6606A (es)
CY (1) CY1111440T1 (es)
CZ (1) CZ20023888A3 (es)
DE (1) DE60143197D1 (es)
DK (1) DK1296951T3 (es)
EA (1) EA004809B1 (es)
EE (1) EE05242B1 (es)
EG (1) EG24189A (es)
ES (1) ES2351958T3 (es)
GC (1) GC0000362A (es)
GE (1) GEP20053492B (es)
GT (1) GT200100091A (es)
HK (1) HK1058932A1 (es)
HN (1) HN2001000110A (es)
HR (1) HRP20020934B1 (es)
HU (1) HU228423B1 (es)
IL (1) IL152582A0 (es)
IN (2) IN2002CH02089A (es)
IS (1) IS2806B (es)
JO (1) JO2216B1 (es)
MA (1) MA26919A1 (es)
ME (1) ME00428B (es)
MX (1) MX230696B (es)
MY (1) MY123569A (es)
NO (1) NO324495B1 (es)
NZ (1) NZ522394A (es)
PA (1) PA8516901A1 (es)
PE (1) PE20011324A1 (es)
PH (1) PH12001001175B1 (es)
PL (1) PL358153A1 (es)
PT (1) PT1296951E (es)
RS (1) RS51541B (es)
SI (1) SI1296951T1 (es)
SK (1) SK287174B6 (es)
SV (1) SV2002000462A (es)
TW (1) TWI303634B (es)
UA (1) UA73355C2 (es)
WO (1) WO2001092230A1 (es)
ZA (1) ZA200209558B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858631B1 (en) 1999-11-29 2005-02-22 Merck & Co., Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
ATE320809T1 (de) 1999-11-29 2006-04-15 Merck Frosst Canada Inc Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-2, 3')bipyridinyl
US6521642B2 (en) * 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
DK2401253T3 (en) 2009-02-27 2016-04-18 Cadila Healthcare Ltd Method for producing etoricoxib
WO2012004677A1 (en) 2010-07-05 2012-01-12 Actavis Group Ptc Ehf Solid state forms of etoricoxib salts
WO2012163839A1 (en) 2011-05-27 2012-12-06 Farma Grs, D.O.O. A process for the preparation of polymorphic form i of etoricoxib
EP2773618A1 (en) 2011-11-03 2014-09-10 Cadila Healthcare Limited An improved process for the preparation of etoricoxib and polymorphs thereof
WO2013075732A1 (en) 2011-11-21 2013-05-30 Synthon Bv Process for making crystalline form i of etoricoxib
EP2601952A1 (en) 2011-12-07 2013-06-12 Zentiva, k.s. Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses
WO2014033526A1 (en) 2012-08-27 2014-03-06 Cadila Healthcare Limited Pharmaceutical compositions of etoricoxib
WO2014041558A2 (en) * 2012-08-27 2014-03-20 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of crystalline etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
CN106632003B (zh) * 2015-12-31 2019-02-12 上海博志研新药物技术有限公司 一种依托考昔的制备方法
CN108069896B (zh) * 2016-11-11 2022-08-12 昆明积大制药股份有限公司 一种依托考昔晶型的制备方法
CN107056691B (zh) * 2017-06-21 2020-03-10 四川尚锐生物医药有限公司 一种制备依托考昔晶型v的方法
CN107417599B (zh) * 2017-06-21 2020-06-09 四川尚锐生物医药有限公司 一种依托考昔晶型的制备方法
MX2017009660A (es) 2017-07-26 2017-11-23 Laboratorios Liomont S A De C V Composicion farmaceutica con un rango de relacion entre el clorhidrato de tramadol y el etoricoxib para su administracion para el tratamiento del dolor.
CN107556231A (zh) * 2017-09-23 2018-01-09 江苏正大清江制药有限公司 一种依托考昔与对硝基苯甲酸形成的盐的晶型及制备方法
CN107417600A (zh) * 2017-09-26 2017-12-01 江苏正大清江制药有限公司 一种依托考昔与呋喃甲酸形成盐的新晶型及制备方法
CN107898787B (zh) * 2017-12-15 2018-11-30 扬子江药业集团上海海尼药业有限公司 一种药物组合物及其制剂和制备方法
MX2018013070A (es) 2017-12-29 2019-10-15 Gruenenthal Gmbh Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor.
CN110143915A (zh) * 2019-06-03 2019-08-20 蚌埠学院 一种依托考昔与对甲苯磺酸形成盐的新晶型及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593994A (en) * 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5739166A (en) * 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
CA2260016C (en) * 1996-07-18 2004-03-09 Merck Frosst Canada Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
CA2329193C (en) * 1998-04-24 2007-01-23 Merck & Co., Inc. Process for synthesizing cox-2 inhibitors
ATE320809T1 (de) * 1999-11-29 2006-04-15 Merck Frosst Canada Inc Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-2, 3')bipyridinyl

Also Published As

Publication number Publication date
NO324495B1 (no) 2007-10-29
CN1443168A (zh) 2003-09-17
AU2001264804B2 (en) 2006-04-06
MY123569A (en) 2006-05-31
BG107237A (bg) 2003-05-30
BRPI0111140B8 (pt) 2021-05-25
PA8516901A1 (es) 2002-04-25
MXPA02011619A (es) 2003-03-27
CY1111440T1 (el) 2015-08-05
NO20025674L (no) 2002-11-26
ME00428B (me) 2011-10-10
SI1296951T1 (sl) 2011-01-31
BR0111140A (pt) 2005-01-11
HU228423B1 (en) 2013-03-28
KR100757699B1 (ko) 2007-09-13
AR028577A1 (es) 2003-05-14
ATE483687T1 (de) 2010-10-15
TWI303634B (en) 2008-12-01
EP1296951A1 (en) 2003-04-02
CA2410234C (en) 2008-05-13
EA200201264A1 (ru) 2003-04-24
KR20030003762A (ko) 2003-01-10
IN2007CH05103A (es) 2008-08-27
SK16702002A3 (sk) 2003-05-02
GC0000362A (en) 2007-03-31
JP2004501116A (ja) 2004-01-15
GT200100091A (es) 2001-12-28
PT1296951E (pt) 2010-12-07
UA73355C2 (en) 2005-07-15
CZ20023888A3 (cs) 2003-02-12
WO2001092230A1 (en) 2001-12-06
PL358153A1 (en) 2004-08-09
PE20011324A1 (es) 2002-01-28
MA26919A1 (fr) 2004-12-20
CA2410234A1 (en) 2001-12-06
DK1296951T3 (da) 2011-01-24
IS2806B (is) 2012-09-15
JP4142621B2 (ja) 2008-09-03
AU6480401A (en) 2001-12-11
SK287174B6 (sk) 2010-02-08
YU89402A (sh) 2005-11-28
HRP20020934A2 (en) 2005-02-28
HK1058932A1 (en) 2004-06-11
NO20025674D0 (no) 2002-11-26
BRPI0111140B1 (pt) 2018-03-13
HUP0302336A2 (hu) 2003-11-28
GEP20053492B (en) 2005-04-25
IL152582A0 (en) 2003-05-29
PH12001001175B1 (en) 2006-08-10
ZA200209558B (en) 2003-10-28
EA004809B1 (ru) 2004-08-26
ES2351958T3 (es) 2011-02-14
EE05242B1 (et) 2009-12-15
SV2002000462A (es) 2002-03-08
IS6630A (is) 2002-11-20
IN2002CH02089A (es) 2005-02-25
EE200200655A (et) 2004-08-16
EG24189A (en) 2008-10-08
CN1227233C (zh) 2005-11-16
JP3665053B2 (ja) 2005-06-29
RS51541B (sr) 2011-06-30
JP2005047927A (ja) 2005-02-24
NZ522394A (en) 2004-05-28
HRP20020934B1 (en) 2012-01-31
CR6606A (es) 2006-02-06
MX230696B (es) 2005-09-19
JO2216B1 (en) 2004-10-07
EP1296951B1 (en) 2010-10-06
BG65855B1 (bg) 2010-03-31
DE60143197D1 (de) 2010-11-18

Similar Documents

Publication Publication Date Title
HN2001000110A (es) 5-cloro -3-(metansulfonilfelino)-6-metil-[2.3] bipiridinilo en forma cristalina pura y proceso para la sintesis
BRPI0402382A (pt) Formas polimórficas de rifaximina, processos para a produção das mesmas e uso das mesmas em preparações medicinais
MEP34408A (en) New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal
CR8975A (es) Proceso para la produccion de derivados de amina opticamente activos
AR057874A1 (es) Aminopirimidinas utiles como inhibidores de quinasa
BRPI0915692B8 (pt) compostos derivados de 1,2,5-oxadiazóis, sua forma sólida, sua composição, bem como seus usos
AR054881A1 (es) Inhibidores macrociclicos de la replicacion del virus de la hepatitis c, un proceso para su preparacion, una composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento para el tratamiento de la hepatitis c
BRPI0720569A2 (pt) Compostos de tetraciclina substituídos
CY1109055T1 (el) 11-((4r,6r)-4,5,6-τριϋδροξυ-3-(r)-υδροξυ-εξυλοκαρβαμοϋλο)-ενδεκαϊνικο οξυ
ES2170732B2 (es) Procedimiento para preparar citalopram purificado
AR048973A1 (es) (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico. proceso de preparacion y composiciones farmaceuticas
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
MY148769A (en) Process for the synthesis of derivatives of 3-amino-tetrahydrofuran-3-carboxylic acid and use thereof as medicaments
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
BR112012017845A2 (pt) novo processo para produção de derivados de benzofenona
DE60117860D1 (de) Kristallisierungsverfahren zur herstellung von sehr reinem para-xylol
CU20220013A7 (es) Proceso industrial para la preparación de estetrol de alta pureza
DOP2001000175A (es) 5-cloro-3-(4-metasulfonilfenilo)-6´-metil-[2,3´] bipiridinilo en forma cristalina pura y proceso para la síntesis
UY29684A1 (es) Derivados de piperidina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones
AR060622A1 (es) Proceso para la preparcion del ester 2-[ 4-(4- fluoro-2 - metil-1h -indol-5- iloxi)-5-metil pirrolo [2,1-f] [ 1,2,4] triazin -6-iloxi] -1- metiletilico del acido [(1r),2s ] -2- aminopropinoico
UA84715C2 (ru) Процесс кристаллизации продукта окисления, который содержит адипиновую кислоту
HUP0300604A2 (hu) Eljárás [6-(4-klór-fenil)-2,2-dimetil-7-fenil-2,3-dihidro-1H-pirrolizin-5-il]-ecetsav és polimorfja előállítására és alkalmazásuk
AR039733A1 (es) Proceso para la obtencion de norelgestromin en distintas relaciones de los isomeros e y z
JPH04211077A (ja) 光学活性な８−メトキシキノロンカルボン酸誘導体及びその製造方法並びにその中間体
RU2357973C1 (ru) Способ получения дипептидов лупанового ряда